- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

EC approval for Otsuka’s treatment for lupus nephritis

The European Commission (EC) has approved Otsuka Pharmaceutical Europe Ltd’s Lupkynis®▼ (voclosporin) in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

Voclosporin is the first and only oral treatment approved in Europe for the treatment of active LN in adult patients and the The EC decision applies to all 27 European Union (EU) member states as well as Iceland, Norway, Liechtenstein and Northern Ireland.

The EC approval is based on the positive results from the pivotal Phase 3 AURORA 1 study1 and the AURORA 2 continuation study2, which demonstrated that treatment with voclosporin, in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids, led to statistically superior complete renal response rates at 52 weeks compared to MMF and low-dose corticosteroids alone3. The safety profile of voclosporin and MMF and low-dose corticosteroids was generally comparable to MMF and low-dose corticosteroids alone3.

The U.S. Food and Drug Administration approved voclosporin in combination with a background immunosuppressive therapy regimen, as the first FDA-approved oral medicine to treat adult patients with active LN in 2021. A decision on marketing authorisation in Great Britain is expected from the UK Medicines and Healthcare products Regulatory Agency in the coming weeks. In addition, a marketing authorisation application was submitted to the Swiss Agency for Therapeutic Products and is currently under review.

Andy Hodge, CEO of Otsuka Pharmaceutical Europe Ltd said: “Today’s EC approval of voclosporin represents a significant development for lupus nephritis patients in Europe, offering the appropriate patients a new treatment option.”

- Advertisement -
Emma Cooper
Emma Cooper
Emma is Content Manager at Pf Media.

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription